Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Abstract
Background As new members of a drug class are developed, head-to-head trials are an important strategy to guide personalised treatment decisions. We assessed two glucagon-like peptide-1 receptor agonists, once-weekly albiglutide and once-daily liraglutide, in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. Methods We undertook this 32-week, open-label, phase 3 non-inferiority study at 162 sites in eight countries: USA (121 sites), Australia (9 sites), Peru (7 sites), Philippines (7 sites), South Korea (5 sites), UK (5 sites), Israel (4 sites), and Spain (4 sites). 841 adult participants (aged ≥18 years) with inadequately controlled type 2 diabetes and a BMI between 20 and 45 kg/m(2) were enrolled and randomised in a 1:1 ratio to receive albiglutide 30 mg once weekly titrated to 50 mg at week 6, or liraglutide 0·6 mg once daily titrated to 1·2 mg at week 1 and 1·8 mg at week 2. The randomisation schedule was generated by an independent randomisation team by the permuted block method with a fixed block size of 16. Participants and investigators were unmasked to treatment. The primary endpoint was change from baseline in HbA1c for albiglutide versus liraglutide, with a 95% CI non-inferiority upper margin of 0·3%. The primary analysis was by modified intention to treat. The study is registered with ClinicalTrials.gov, number NCT01128894. Findings 422 patients were randomly allocated to the albigultide group and 419 to the liraglutide group; 404 patients in the abliglutide group and 408 in the liraglutide group received the study drugs. The primary endpoint analysis was done on the modified intention-to-treat population, which included 402 participants in the albiglutide group and 403 in the liraglutide group. Model-adjusted change in HbA1c from baseline to week 32 was -0·78% (95% CI -0·87 to -0·69) in the albigludite group and -0·99% (-1·08 to -0·90) in the liraglutide group; treatment difference was 0·21% (0·08-0·34; non-inferiority p value=0·0846). Injection-site reactions occurred in more patients given albiglutide than in those given liraglutide (12·9% vs 5·4%; treatment difference 7·5% [95% CI 3·6-11·4]; p=0·0002), whereas the opposite was the case for gastrointestinal events, which occurred in 49·0% of patients in the liraglutide group versus 35·9% in the albiglutide group (treatment difference -13·1% [95% CI -19·9 to -6·4]; p=0·00013). Interpretation Patients who received once-daily liraglutide had greater reductions in HbA1c than did those who received once-weekly albiglutide. Participants in the albiglutide group had more injection-site reactions and fewer gastrointestinal events than did those in the liraglutide group. Funding GlaxoSmithKline.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies of other drug classes and different GLP1-RAs have shown cardiovascular outcome benefit in association with little or no weight loss.
“This is in keeping with studies of other drug classes and different GLP1-RAs, which have shown cardiovascular outcome benefit in association with little or no weight loss.24”
From Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial (2025) · cites this paper as [24]
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · see citing works
Self-citationDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works
Self-citationBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · see citing works
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350 · see citing works
Zinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290 · see citing works
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Garber, A. J., Thomsen, A. B., Hartvig, H. B., Davies, M. J., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 253 · see citing works
Self-citationPotential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works
Self-citationMatthews, J. E., Stewart, M. W., Boever, E. H. D., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198 · see citing works
Self-citationBush, M., Matthews, J. E., Boever, E. H. D., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., & Stewart, M. W. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00992.x · Cited by 180 · see citing works
Self-citationBrain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity
Cabou, C., Campistron, G., Marsollier, N., Leloup, C., Cruciani‐Guglielmacci, C., Pénicaud, L., Drucker, D. J., Magnan, C., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db08-0121 · Cited by 121 · see citing works
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104 · see citing works
Brod, M. I., Skovlund, S. E., & Wittrup-Jensen, K. U. (2006) · Quality of Life Research · doi:10.1007/s11136-005-1624-6 · Cited by 93 · see citing works
Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects
Hayes, M. R. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.02.017 · Cited by 74 · see citing works
Gurney, K., Malloy, Shan, S., Yan, Y., & Chen (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34241 · Cited by 22 · see citing works
Rosenstock, J., & Stewart, M. W. (2010) · Drugs of the Future · doi:10.1358/dof.2010.035.09.1516042 · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Self-citationDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · see citing works
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · see citing works
“107 Further, serious risks associated with Tanzeum use include pancreatitis, acute kidney injury, renal impairment, and pneumonia, further limiting its use in speci fi c conditions or susceptible patients.”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · see citing works
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · see citing works
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
Self-citationSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · see citing works
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · see citing works
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · see citing works
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · see citing works
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · see citing works
Self-citationHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 418 · see citing works
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · see citing works
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · see citing works
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398 · see citing works
Self-citationBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · see citing works
Self-citationA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · see citing works
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305 · see citing works
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289 · see citing works
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · see citing works
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S. P., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 272 · see citing works
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265 · see citing works
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253 · see citing works
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 255 · see citing works
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245 · see citing works
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 230 · see citing works
Åhrén, B., JOHNSON, S. L., Stewart, M. W., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228 · see citing works
Self-citationBrown, E. E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222 · see citing works
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217 · see citing works
Rosenstock, J., Fonseca, V. A., Gross, J. L., Ratner, R. E., Åhrén, B., Chow, F. C. C., Yang, F., Miller, D. M., JOHNSON, S. L., Stewart, M. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0001 · Cited by 212 · see citing works
Self-citationBattle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 185 · see citing works
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · see citing works
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159 · see citing works
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156 · see citing works
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · see citing works
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · see citing works
Liraglutide and obesity: a review of the data so far
Ladenheim, E. E. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 147 · see citing works
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143 · see citing works
Self-citationWeissman, P. N., Carr, M. C., Ye, J., Cirkel, D. T., Stewart, M. W., Perry, C., & Pratley, R. E. (2014) · Diabetologia · doi:10.1007/s00125-014-3360-3 · Cited by 135 · see citing works
Self-citationDeanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01375-3 · Cited by 143 · see citing works
Nauck, M. A., Stewart, M. W., Perkins, C., Jones-Leone, A. R., Yang, F., Perry, C., Reinhardt, R. R., & Rendell, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3795-1 · Cited by 125 · see citing works
Self-citationPharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 115 · see citing works
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 115 · see citing works
Reusch, J. E. B., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C., Reinhardt, R., & Bode, B. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12382 · Cited by 110 · see citing works
Self-citationG Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108 · see citing works
Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., Loredo, L. D., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 105 · see citing works
Self-citationTran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed Central · Cited by 102 · see citing works
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101 · see citing works
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101 · see citing works
Home, P., Shamanna, P., Stewart, M. W., Yang, F., Miller, M. J., Perry, C., & Carr, M. C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12414 · Cited by 100 · see citing works
Self-citationComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99 · see citing works
Burcelin, R., & Gourdy, P. (2016) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 97 · see citing works
Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 98 · see citing works
GLP ‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. A. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 97 · see citing works
Green, J. B., Hernandez, A. F., D’Agostino, R. B., Granger, C. B., Janmohamed, S. G., Jones, N. P., Leiter, L. A., Noronha, D., Russell, R., Sigmon, K. N., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.030 · Cited by 94 · see citing works
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 91 · see citing works
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 92 · see citing works
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 87 · see citing works
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.
Miller, B. R., Nguyen, H. T., Hu, C. J.-H., Lin, C., & Nguyen, Q. P. H. (2014) · PubMed Central · Cited by 86 · see citing works
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Torres-Vega, E., Linz, B. M., Eggertsen, C. E., Mulvey, J. F., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 90 · see citing works
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83 · see citing works
Cardiovascular outcome trials of glucose-lowering medications: an update
Home, P. D. (2019) · Diabetologia · doi:10.1007/s00125-018-4801-1 · Cited by 82 · see citing works
Araki, E., Inagaki, N., Tanizawa, Y., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12540 · Cited by 81 · see citing works
Horowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12872 · Cited by 79 · see citing works
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79 · see citing works
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
Boyle, J. G., Livingstone, R., & Petrie, J. R. (2018) · Clinical Science · doi:10.1042/cs20171299 · Cited by 79 · see citing works
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Fisher, M., Petrie, M. C., Ambery, P., Donaldson, J., Ye, J., & McMurray, J. J. V. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00233-8 · Cited by 79 · see citing works
Self-citationRole of glucagon-like peptide 1 receptor agonists in management of obesity
Isaacs, D. M., Prasad‐Reddy, L., & Srivastava, S. B. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150990 · Cited by 78 · see citing works
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74 · see citing works
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71 · see citing works
Adetunji, O., Kalra, S., Baruah, M., Sahay, R. K., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 72 · see citing works
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65 · see citing works
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 65 · see citing works
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 64 · see citing works
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 65 · see citing works
Singh, P., Taufeeq, M., Pesavento, T. E., Washburn, K., Walsh, D., & Meng, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13964 · Cited by 61 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., Júnior, J. C. D. L., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 61 · see citing works
Trujillo, J. M., & Nuffer, W. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014545807 · Cited by 59 · see citing works
Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., & Takamura, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12602 · Cited by 58 · see citing works
Harris, K. B., & McCarty, D. J. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57 · see citing works
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E. A., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12541 · Cited by 56 · see citing works
Injectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 56 · see citing works
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54 · see citing works
Dalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13128 · Cited by 54 · see citing works
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 52 · see citing works
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51 · see citing works
Thompson, A. M., & Trujillo, J. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564180 · Cited by 50 · see citing works
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50 · see citing works
Albiglutide: First Global Approval
Poole, R. M., & Nowlan, M. L. (2014) · Drugs · doi:10.1007/s40265-014-0228-2 · Cited by 49 · see citing works
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 48 · see citing works
Drab, S. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47 · see citing works
Jain, A., Ali, A., Martínez, J. J. G., HRAMIAK, I. M., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 47 · see citing works
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 45 · see citing works
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43 · see citing works
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43 · see citing works
Immunogenicity of long-lasting recombinant factor VIII products
Ing, M., Gupta, N., Teyssandier, M., Maillère, B., Pallardy, M. J., Delignat, S., & Lacroix‐Desmazes, S. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.12.006 · Cited by 43 · see citing works
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 43 · see citing works
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 43 · see citing works
- Authors
- Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., & Rosenstock, J.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Diabeteszentrum Bad Lauterberg (DE)
- Heartlands Hospital (GB)
- Duke University (US)
- University of Alabama at Birmingham (US)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Pratley, Richard E
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 2
- Issue
- 4
- Pages
- 289-297
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2128825255
- Cited by
- 326
- References
- 24
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 18 · 2023: 6 · 2022: 8 · 2021: 19 · 2020: 14 · 2019: 22 · 2018: 30 · 2017: 46 · 2016: 51 · 2015: 47 · 2014: 34 · 2013: 1
- FWCI
- 48.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, albiglutide, liraglutide, GLP-1 receptor agonists, HbA1c, inadequate glycemic control, oral antidiabetic drugs, non-inferiority, dose titration, head-to-head comparison, personalized treatment, body mass index, adverse events
- MeSH terms
- Liraglutide, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
